Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.34 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27259514 | 0.80 | MBOAT4 (0.46) | MBOAT4CDK5CDK5R1CYP19A1GRIN1 | |
| SCHEMBL8604667 | 0.80 | MBOAT4 (0.42) | MBOAT4CDK5CDK5R1CYP19A1GRIN1 | |
| SCHEMBL8542483 | 0.79 | MBOAT4 (0.37) | MBOAT4CDK5CDK5R1CYP19A1SRD5A1 | |
| SCHEMBL7741691 | 0.75 | SRD5A2 (0.41) | MBOAT4SRD5A1SRD5A2GRIN1GRIN2B | |
| SCHEMBL7711769 | 0.74 | MBOAT4 (0.38) | MBOAT4CDK5CDK5R1CYP19A1SRD5A1 | |
| SCHEMBL8528297 | 0.73 | HSD17B7 (0.42) | MBOAT4SRD5A1SRD5A2 | |
| SCHEMBL8823337 | 0.73 | MBOAT4 (0.38) | MBOAT4SRD5A2 | |
| SCHEMBL8823339 | 0.73 | MBOAT4 (0.38) | MBOAT4SRD5A2 | |
| SCHEMBL28119193 | 0.72 | CDK5 (0.43) | MBOAT4CDK5CDK5R1CYP19A1GRIN1 | |
| SCHEMBL5596628 | 0.72 | SRD5A1 (0.54) | SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1053672-C | Azasteroid compounds for the treatment of prostatic hypertrophy | SANKYO CO (JP) | 2000-06-21 | — | — | CN | disclosed |